300683 Stock Overview
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wuhan Hiteck Biological Pharma Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.90 |
| 52 Week High | CN¥51.64 |
| 52 Week Low | CN¥18.80 |
| Beta | -0.30 |
| 1 Month Change | -11.58% |
| 3 Month Change | -24.25% |
| 1 Year Change | -33.22% |
| 3 Year Change | -44.01% |
| 5 Year Change | -26.79% |
| Change since IPO | -51.72% |
Recent News & Updates
Shareholder Returns
| 300683 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 3.4% | 0.3% | 1.6% |
| 1Y | -33.2% | -24.2% | -15.1% |
Return vs Industry: 300683 underperformed the CN Biotechs industry which returned -24.2% over the past year.
Return vs Market: 300683 underperformed the CN Market which returned -15.1% over the past year.
Price Volatility
| 300683 volatility | |
|---|---|
| 300683 Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 300683's share price has been volatile over the past 3 months.
Volatility Over Time: 300683's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,346 | Ya Chen | www.hiteck.com.cn |
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit.
Wuhan Hiteck Biological Pharma Co.,Ltd Fundamentals Summary
| 300683 fundamental statistics | |
|---|---|
| Market cap | CN¥2.94b |
| Earnings (TTM) | -CN¥135.90m |
| Revenue (TTM) | CN¥595.54m |
5.0x
P/S Ratio-22.1x
P/E RatioIs 300683 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300683 income statement (TTM) | |
|---|---|
| Revenue | CN¥595.54m |
| Cost of Revenue | CN¥346.36m |
| Gross Profit | CN¥249.18m |
| Other Expenses | CN¥385.07m |
| Earnings | -CN¥135.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | 41.84% |
| Net Profit Margin | -22.82% |
| Debt/Equity Ratio | 2.1% |
How did 300683 perform over the long term?
See historical performance and comparison